Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELING
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 VENDOR SHARE ANALYSIS
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.2.1 POLITICAL FACTORS
4.2.2 ECONOMIC FACTORS
4.2.3 SOCIAL FACTORS
4.2.4 TECHNOLOGICAL FACTORS
4.2.5 ENVIRONMENTAL FACTORS
4.2.6 LEGAL FACTORS
4.3 R&D ANALYSIS
4.3.1 COMPARATIVE ANALYSIS
4.3.2 DRUG DEVELOPMENTAL LANDSCAPE
4.3.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
4.3.4 THERAPEUTIC ASSESSMENT
4.3.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
4.4 HEALTHCARE TARIFFS IMPACT ANALYSIS
4.4.1 OVERVIEW
4.4.2 TARIFF STRUCTURES
4.4.2.1 GLOBAL VS. REGIONAL TARIFF STRUCTURES
4.4.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS
4.4.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS
4.4.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS
4.4.3.3 KEY TRADE AGREEMENTS AFFECTING TARIFFS
4.4.4 IMPACT OF TARIFFS ON PROVIDERS AND PATIENTS
4.4.4.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES
4.4.4.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE
4.4.4.3 TARIFFS AND MEDICAL TOURISM
4.4.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS
4.4.5.1 WTO REGULATIONS
4.4.5.2 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN
4.4.5.3 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS
4.4.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY
4.4.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR
4.5 PATENT ANALYSIS-
4.6 MARKETED DRUG ANALYSIS
4.6.1 10-YEAR MARKET FORECAST
4.6.2 DRUGS
4.6.3 BRANDED DRUGS
4.6.4 GENERIC DRUGS
4.6.5 THERAPEUTIC INDICATION
4.6.6 PHARMACOLOGICAL CLASS OF THE DRUG
4.6.7 DRUG PRIMARY INDICATION
4.6.8 MARKET STATUS
4.6.9 MEDICATION TYPE
4.6.10 DRUG DOSAGE FORM
4.6.11 DOSAGE AVAILABILITY
4.6.12 PACKAGING TYPE
4.6.13 DRUG ROUTE OF ADMINISTRATION
4.6.14 DOSING FREQUENCY
4.6.15 DRUG INSIGHT
4.6.16 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES
4.6.17 REGULATORY MILESTONE, SAFETY DATA, AND EFFICACY DATA
4.6.18 MARKET EXCLUSIVITY DATA
4.6.19 FORECAST MARKET OUTLOOK
4.6.20 CROSS COMPETITION
4.6.21 THERAPEUTIC PORTFOLIO
4.6.22 CURRENT DEVELOPMENT SCENARIO
4.7 MARKET ACCESS
4.7.1 10-YEAR MARKET FORECAST
4.7.2 CLINICAL TRIAL RECENT UPDATES
4.7.3 ANNUAL NEW FDA-APPROVED DRUGS
4.7.4 DRUG MANUFACTURER AND DEALS
4.7.5 MAJOR DRUG UPTAKE
4.7.6 CURRENT TREATMENT PRACTICES
4.7.7 IMPACT OF UPCOMING THERAPY
4.8 EPIDEMOLOGY
4.8.1 INCIDENCE BY GENDER: POCT-RELEVANT CONDITIONS
4.8.2 TREATMENT RATE: IMPACT ON POCT
4.8.3 MORTALITY RATE: THE NEED FOR TIMELY DIAGNOSIS
4.8.4 DRUG ADHERENCE AND THERAPY SWITCH: POCT'S ROLE IN MANAGEMENT
4.8.5 PATIENT TREATMENT SUCCESS RATES: THE POCT ADVANTAGE
4.9 SUPPLY CHAIN ECOSYSTEM
4.9.1 PROMINENT COMPANIES
4.9.2 KEY COMPONENTS OF THE ECOSYSTEM:
4.9.3 SMALL & MEDIUM SIZE COMPANIES (INNOVATORS)
4.9.4 END USERS
4.1 INNOVATION TRACKER & STRATEGIC ANALYSIS
4.10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
4.10.1.1 JOINT VENTURES
4.10.1.2 MERGERS & ACQUISITIONS
4.10.1.3 LICENSING & PARTNERSHIPS
4.10.1.4 TECHNOLOGY COLLABORATIONS
4.10.1.5 STRATEGIC DIVESTMENTS
4.10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
4.10.3 STAGE OF DEVELOPMENT
4.10.4 TIMELINES & MILESTONES
4.10.5 INNOVATION STRATEGIES & METHODOLOGIES
4.10.6 RISK ASSESSMENT & MITIGATION
4.10.7 FUTURE OUTLOOK
4.11 PIPELINE ANALYSIS – CANADA AND USA POINT OF CARE TESTING MARKET
4.11.1 CLINICAL TRIALS AND PHASE ANALYSIS
4.11.2 TECHNOLOGY PIPELINE
4.11.3 PHASE III CANDIDATES
4.11.4 PHASE II CANDIDATES
4.11.5 PHASE I CANDIDATES
4.11.6 OTHERS (PRE-CLINICAL AND RESEARCH)
4.11.7 CONCLUSION
5 REGULATION COVERAGE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES INCREASING DEMAND FOR RAPID, DECENTRALIZED DIAGNOSTICS
6.1.2 ADVANCED HEALTHCARE INFRASTRUCTURE AND STRONG MOBILE/WEARABLE ADOPTION IN CANADA AND THE U.S.
6.1.3 GROWING PATIENT PREFERENCE FOR FAST, CONVENIENT, NEAR-PATIENT TESTING OPTIONS
6.1.4 INCREASING GOVERNMENT INITIATIVES AND FUNDING TO SUPPORT DIGITAL HEALTH AND DECENTRALIZED DIAGNOSTICS
6.2 RESTRAINTS
6.2.1 HIGH COSTS FOR ADVANCED POCT DEVICES AND REAGENTS
6.2.2 VARIABILITY IN DEVICE PERFORMANCE AND QUALITY ACROSS BRANDS, COMPLICATING STANDARDIZATION AND CLINICAL ADOPTION
6.3 OPPORTUNITIES
6.3.1 INCREASING USE IN DRUG ABUSE, INFECTIOUS DISEASE, AND ONCOLOGY SCREENING, DRIVING MARKET DIVERSIFICATION
6.3.2 EXPANDING USE OF MOLECULAR POCT AND LATERAL FLOW IMMUNOASSAYS, INCLUDING PHARMACIES AND REMOTE/RURAL CARE
6.3.3 INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR ENHANCED DIAGNOSTIC ACCURACY AND CLINICAL DECISION SUPPORT
6.4 CHALLENGES
6.4.1 MAINTAINING ACCURACY, RELIABILITY, AND REGULATION COMPLIANCE ACROSS DECENTRALIZED TESTING ENVIRONMENTS
6.4.2 ADDRESSING DATA PRIVACY AND CYBERSECURITY RISKS AS MORE POCT DEVICES CONNECT TO HEALTH NETWORKS
7 CANADA AND U.S. POINT OF CARE TESTING MARKET, BY PRODUCT/DISEASE
7.1 OVERVIEW
7.2 RESPIRATORY INFECTION
7.2.1 SARS-COV-2
7.2.2 INFLUENZA A/B
7.2.3 RESPIRATORY SYNCYTIAL VIRUS (RSV)
7.2.4 BORDETELLA PERTUSSIS
7.2.5 OTHERS
7.3 GASTROENTERIC INFECTIONS
7.3.1 CLOSTRIDIOIDES DIFFICILE
7.3.2 NOROVIRUS
7.3.3 ROTAVIRUS
7.3.4 SALMONELLA, SHIGELLA, CAMPYLOBACTER, E. COLI (STEC)
7.3.5 GIARDIA
7.4 SEXUALLY TRANSMITTED DISEASE (STD)
7.5 HEPATITIS
7.6 BLOODSTREAM INFECTIONS (BSI)
7.7 BLOOD YEAST INFECTIONS (FUNGAL BSI)
7.8 OTHERS
8 CANADA AND U.S. OF CARE TESTING MARKET, BY METHOD/TECHNOLOGY
8.1 OVERVIEW
8.2 NAAT (NUCLEIC ACID AMPLIFICATION TESTS)
8.3 LAMP (LOOP-MEDIATED ISOTHERMAL AMPLIFICATION)
8.4 MICROFLUIDICS / LAB-ON-A-CHIP
8.5 OTHERS
9 CANADA AND U.S. POINT OF CARE TESTING MARKET, BY PANEL TYPE
9.1 OVERVIEW
9.2 SIMPLEX ASSAY
9.3 MULTIPLEX PANEL (SYNDROMIC TESTING)
9.4 DUPLEX ASSAY
9.5 TRIPLEX ASSAY
10 CANADA AND U.S. POINT OF CARE TESTING MARKET, BY TESTING LOCATION
10.1 OVERVIEW
10.2 LABORATORY BASED POINT-OF-CARE-TESTING (POCT)
10.3 AT-HOME POINT-OF-CARE-TESTING (POCT)
11 CANADA AND U.S. POINT OF CARE TESTING MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 HOME CARE
11.4 CLINICS
11.5 LABORATORIES
11.6 AMBULATORY SURGERY CENTERS
11.7 ELDERLY CARE CENTERS
11.8 OTHERS
12 CANADA AND U.S. POINT OF CARE TESTING MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 ONLINE SALES
12.5 OTHERS
13 CANADA AND U.S. POINT OF CARE TESTING MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: U.S.
13.2 COMPANY SHARE ANALYSIS: CANADA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 DANAHER CORPORATION.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.2 F. HOFFMANN-LA ROCHE LTD
15.2.1 COMPANY SNAPSHOT
15.2.2 RECENT FINANCIALS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENTS
15.3 SIEMENS HEALTHINEERS AG
15.3.1 COMPANY SNAPSHOT
15.3.2 RECENT FINANCIALS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENTS
15.4 BD
15.4.1 COMPANY SNAPSHOT
15.4.2 RECENT FINANCIALS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENTS
15.5 ABBOTT
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 AGILENT TECHNOLOGIES INC.
15.6.1 COMPANY SNAPSHOT
15.6.2 RECENT FINANCIALS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENTS
15.7 ABAXIS, INC.
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 BINX HEALTH, INC.
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 BIOMERIEUX
15.9.1 COMPANY SNAPSHOT
15.9.2 RECENT FINANCIALS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 BIO-RAD LABORATORIES, INC.
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 CREATIVE DIAGNOSTICS
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 CARDINAL HEALTH
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 CANADIAN HOSPITAL SPECIALTIES LIMITED
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 EKF DIAGNOSTICS HOLDINGS PLC.
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENT
15.15 HENRY SCHEIN, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 HIPRO BIOTECHNOLOGY CO.,LTD.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENTS
15.17 MEDLINE INDUSTRIES, LP
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 MERIDIAN BIOSCIENCE, INC
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 NIPRO
15.19.1 COMPANY SNAPSHOT
15.19.2 RECENT FINANCIALS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENTS
15.2 NOVA BIOMEDICAL
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.21 ORASURE TECHNOLOGIES INC
15.21.1 COMPANY SNAPSHOT
15.21.2 REVENUE ANALYSIS
15.21.3 PRODUCT PORTFOLIO
15.21.4 RECENT DEVELOPMENT
15.22 PTS DIAGNOSTICS
15.22.1 COMPANY SNAPSHOT
15.22.2 PRODUCT PORTFOLIO
15.22.3 RECENT DEVELOPMENT
15.23 QIAGEN
15.23.1 COMPANY SNAPSHOT
15.23.2 REVENUE ANALYSIS
15.23.3 PRODUCT PORTFOLIO
15.23.4 RECENT DEVELOPMENT
15.24 QUANTUMDX GROUP LTD.
15.24.1 COMPANY SNAPSHOT
15.24.2 PRODUCT PORTFOLIO
15.24.3 RECENT DEVELOPMENT
15.25 QUIDELORTHO CORPORATION.
15.25.1 COMPANY SNAPSHOT
15.25.2 REVENUE ANALYSIS
15.25.3 PRODUCT PORTFOLIO
15.25.4 RECENT DEVELOPMENTS
15.26 RADIOMETER MEDICAL APS
15.26.1 COMPANY SNAPSHOT
15.26.2 PRODUCT PORTFOLIO
15.26.3 RECENT UPDATES
15.27 SANNER
15.27.1 COMPANY SNAPSHOT
15.27.2 PRODUCT PORTFOLIO
15.27.3 RECENT DEVELOPMENT
15.28 SEKISUI DIAGNOSTICS
15.28.1 COMPANY SNAPSHOT
15.28.2 PRODUCT PORTFOLIO
15.28.3 RECENT DEVELOPMENT
15.29 SYSMEX CORPORATION
15.29.1 COMPANY SNAPSHOT
15.29.2 REVENUE ANALYSIS
15.29.3 PRODUCT PORTFOLIO
15.29.4 RECENT DEVELOPMENT
15.3 SANGUNIA
15.30.1 COMPANY SNAPSHOT
15.30.2 PRODUCT PORTFOLIO
15.30.3 RECENT DEVELOPMENTS
15.31 THE STEVENS COMPANY LIMITED
15.31.1 COMPANY SNAPSHOT
15.31.2 PRODUCT PORTFOLIO
15.31.3 RECENT DEVELOPMENT
15.32 THERMO FISHER SCIENTIFIC INC.
15.32.1 COMPANY SNAPSHOT
15.32.2 REVENUE ANALYSIS
15.32.3 PRODUCT PORTFOLIO
15.32.4 RECENT DEVELOPMENT
15.33 TRIMEDIC INC
15.33.1 COMPANY SNAPSHOT
15.33.2 PRODUCT PORTFOLIO
15.33.3 RECENT DEVELOPMENT
15.34 TRINITY BIOTECH
15.34.1 COMPANY SNAPSHOT
15.34.2 REVENUE ANALYSIS
15.34.3 PRODUCT PORTFOLIO
15.34.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
List of Table
TABLE 1 PHASE-WISE DISTRIBUTION
TABLE 2 REGULATORY COVERAGE
TABLE 3 U.S. POINT OF CARE TESTING MARKET, BY PRODUCT/DISEASE, 2018-2032 (USD THOUSAND)
TABLE 4 CANADA POINT OF CARE TESTING MARKET, BY PRODUCT/DISEASE, 2018-2032 (USD THOUSAND)
TABLE 5 U.S. RESPIRATORY INFECTIONS IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 CANADA RESPIRATORY INFECTIONS IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 7 U.S. GASTROENTERIC INFECTIONS IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 CANADA GASTROENTERIC INFECTIONS IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 U.S. SEXUALLY TRANSMITTED DISEASE (STD) IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 10 CANADA SEXUALLY TRANSMITTED DISEASE (STD) IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 U.S. HEPATITIS IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 CANADA HEPATITIS IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 13 U.S. BLOODSTREAM INFECTIONS (BSI) IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 CANADA BLOODSTREAM INFECTIONS (BSI) IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 15 U.S. BLOOD YEAST INFECTIONS (FUNGAL BSI) IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 CANADA BLOOD YEAST INFECTIONS (FUNGAL BSI) IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 17 U.S. OTHERS IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 18 CANADA OTHERS IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 19 U.S. POINT OF CARE TESTING MARKET, BY METHOD/TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 20 CANADA POINT OF CARE TESTING MARKET, BY METHOD/TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 21 U.S. NAAT (NUCLEIC ACID AMPLIFICATION TESTS) IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 22 CANADA NAAT (NUCLEIC ACID AMPLIFICATION TESTS) IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 23 U.S. POINT OF CARE TESTING MARKET, BY PANEL TYPE, 2018-2032 (USD THOUSAND)
TABLE 24 CANADA POINT OF CARE TESTING MARKET, BY PANEL TYPE, 2018-2032 (USD THOUSAND)
TABLE 25 U.S. MULTIPLEX PANEL (SYNDROMIC TESTING) IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 26 CANADA MULTIPLEX PANEL (SYNDROMIC TESTING) IN POINT OF CARE TESTING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 27 U.S. POINT OF CARE TESTING MARKET, BY TESTING LOCATION, 2018-2032 (USD THOUSAND)
TABLE 28 CANADA POINT OF CARE TESTING MARKET, BY TESTING LOCATION, 2018-2032 (USD THOUSAND)
TABLE 29 U.S. POINT OF CARE TESTING MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 30 CANADA POINT OF CARE TESTING MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 31 U.S. POINT OF CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 32 CANADA POINT OF CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 CANADA AND U.S. POINT OF CARE TESTING MARKET: SEGMENTATION
FIGURE 2 GEOGRAPHICAL SCOPE
FIGURE 3 CANADA AND U.S. POINT OF CARE TESTING MARKET: DATA TRIANGULATION
FIGURE 4 CANADA AND U.S. POINT OF CARE TESTING MARKET: DROC ANALYSIS
FIGURE 5 U.S. POINT OF CARE TESTING MARKET: COUNTRYWISE MARKET ANALYSIS
FIGURE 6 CANADA POINT OF CARE TESTING MARKET: COUNTRYWISE MARKET ANALYSIS
FIGURE 7 CANADA AND U.S. POINT OF CARE TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 8 CANADA AND U.S. POINT OF CARE TESTING MARKET: MULTIVARIATE MODELING
FIGURE 9 U.S. POINT OF CARE TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 10 CANADA POINT OF CARE TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 11 CANADA AND U.S. POINT OF CARE TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 12 U.S. POINT OF CARE TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 13 CANADA POINT OF CARE TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 14 U.S. POINT OF CARE TESTING MARKET: END USER COVERAGE GRID
FIGURE 15 CANADA POINT OF CARE TESTING MARKET: END USER COVERAGE GRID
FIGURE 16 CANADA AND U.S. POINT OF CARE TESTING MARKET: SEGMENTATION
FIGURE 17 CANADA POINT OF CARE TESTING MARKET: EXECUTIVE SUMMARY
FIGURE 18 U.S. POINT OF CARE TESTING MARKET: EXECUTIVE SUMMARY
FIGURE 19 SEVEN SEGMENTS COMPRISE THE U.S. POINT OF CARE TESTING MARKET, BY PRODUCT/DISEASE (2024)
FIGURE 20 SEVEN SEGMENTS COMPRISE THE CANADA POINT OF CARE TESTING MARKET, BY PRODUCT/DISEASE (2024)
FIGURE 21 STRATEGIC DECISIONS
FIGURE 22 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES INCREASING DEMAND FOR RAPID, DECENTRALIZED DIAGNOSTICS IS DRIVING THE GROWTH OF CANADA POINT OF CARE TESTING MARKET FROM 2025 TO 2032
FIGURE 23 GROWING PATIENT PREFERENCE FOR FAST, CONVENIENT, NEAR-PATIENT TESTING OPTIONS IS DRIVING THE GROWTH OF U.S. POINT OF CARE TESTING MARKET FROM 2025 TO 2032
FIGURE 24 THE RESPIRATORY INFECTIONS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANADA POINT OF CARE TESTING MARKET IN 2025 AND 2032
FIGURE 25 THE RESPIRATORY INFECTIONS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. POINT OF CARE TESTING MARKET IN 2025 AND 2032
FIGURE 26 PESTEL ANALYSIS
FIGURE 27 PATENT FILINGS ACROSS SEVERAL KEY JURISDICTIONS:
FIGURE 28 U.S.: KEY APPLICANTS V/S NUMBER OF PATENTS.
FIGURE 29 CANADA: KEY APPLICANTS V/S NUMBER OF PATENTS
FIGURE 30 U.S.: IPC CODES V/S PATENT COUNT
FIGURE 31 CANADA: IPC CODES V/S PATENT COUNT.
FIGURE 32 U.S.: YEAR V/S NUMBER OF PATENT PUBLISHED
FIGURE 33 CANADA: YEAR V/S NUMBER OF PATENT PUBLISHED
FIGURE 34 DROC ANALYSIS
FIGURE 35 U.S. POINT OF CARE TESTING MARKET: BY PRODUCT/DISEASE, 2024
FIGURE 36 U.S. POINT OF CARE TESTING MARKET: BY PRODUCT/DISEASE, 2025 TO 2032 (USD THOUSAND)
FIGURE 37 U.S. POINT OF CARE TESTING MARKET: BY PRODUCT/DISEASE, CAGR (2025- 2032)
FIGURE 38 U.S. POINT OF CARE TESTING MARKET: BY PRODUCT/DISEASE, LIFELINE CURVE
FIGURE 39 CANADA POINT OF CARE TESTING MARKET: BY PRODUCT/DISEASE, 2024
FIGURE 40 CANADA POINT OF CARE TESTING MARKET: BY PRODUCT/DISEASE, 2025 TO 2032 (USD THOUSAND)
FIGURE 41 CANADA POINT OF CARE TESTING MARKET: BY PRODUCT/DISEASE, CAGR (2025- 2032)
FIGURE 42 CANADA POINT OF CARE TESTING MARKET: BY PRODUCT/DISEASE, LIFELINE CURVE
FIGURE 43 U.S. POINT OF CARE TESTING MARKET: BY METHOD/TECHNOLOGY, 2024
FIGURE 44 U.S. POINT OF CARE TESTING MARKET: BY METHOD/TECHNOLOGY, 2025 TO 2032 (USD THOUSAND)
FIGURE 45 U.S. POINT OF CARE TESTING MARKET: BY METHOD/TECHNOLOGY, CAGR (2025- 2032)
FIGURE 46 U.S. POINT OF CARE TESTING MARKET: BY METHOD/TECHNOLOGY, LIFELINE CURVE
FIGURE 47 CANADA POINT OF CARE TESTING MARKET: BY METHOD/TECHNOLOGY, 2024
FIGURE 48 CANADA POINT OF CARE TESTING MARKET: BY METHOD/TECHNOLOGY, 2025 TO 2032 (USD THOUSAND)
FIGURE 49 CANADA POINT OF CARE TESTING MARKET: BY METHOD/TECHNOLOGY, CAGR (2025- 2032)
FIGURE 50 CANADA POINT OF CARE TESTING MARKET: BY METHOD/TECHNOLOGY, LIFELINE CURVE
FIGURE 51 U.S. POINT OF CARE TESTING MARKET: BY PANEL TYPE, 2024
FIGURE 52 U.S. POINT OF CARE TESTING MARKET: BY PANEL TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 53 U.S. POINT OF CARE TESTING MARKET: BY PANEL TYPE, CAGR (2025- 2032)
FIGURE 54 U.S. POINT OF CARE TESTING MARKET: BY PANEL TYPE, LIFELINE CURVE
FIGURE 55 CANADA POINT OF CARE TESTING MARKET: BY PANEL TYPE, 2024
FIGURE 56 CANADA POINT OF CARE TESTING MARKET: BY PANEL TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 57 CANADA POINT OF CARE TESTING MARKET: BY PANEL TYPE, CAGR (2025- 2032)
FIGURE 58 CANADA POINT OF CARE TESTING MARKET: BY PANEL TYPE, LIFELINE CURVE
FIGURE 59 U.S. POINT OF CARE TESTING MARKET: BY TESTING LOCATION, 2024
FIGURE 60 U.S. POINT OF CARE TESTING MARKET: BY TESTING LOCATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 61 U.S. POINT OF CARE TESTING MARKET: BY TESTING LOCATION, CAGR (2025- 2032)
FIGURE 62 U.S. POINT OF CARE TESTING MARKET: BY TESTING LOCATION, LIFELINE CURVE
FIGURE 63 CANADA POINT OF CARE TESTING MARKET: BY TESTING LOCATION, 2024
FIGURE 64 CANADA POINT OF CARE TESTING MARKET: BY TESTING LOCATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 65 CANADA POINT OF CARE TESTING MARKET: BY TESTING LOCATION, CAGR (2025- 2032)
FIGURE 66 CANADA POINT OF CARE TESTING MARKET: BY TESTING LOCATION, LIFELINE CURVE
FIGURE 67 U.S. POINT OF CARE TESTING MARKET: BY END USER, 2024
FIGURE 68 U.S. POINT OF CARE TESTING MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)
FIGURE 69 U.S. POINT OF CARE TESTING MARKET: BY END USER, CAGR (2025- 2032)
FIGURE 70 U.S. POINT OF CARE TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 71 CANADA POINT OF CARE TESTING MARKET: BY END USER, 2024
FIGURE 72 CANADA POINT OF CARE TESTING MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)
FIGURE 73 CANADA POINT OF CARE TESTING MARKET: BY END USER, CAGR (2025- 2032)
FIGURE 74 CANADA POINT OF CARE TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 75 U.S. POINT OF CARE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 76 U.S. POINT OF CARE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)
FIGURE 77 U.S. POINT OF CARE TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025- 2032)
FIGURE 78 U.S. POINT OF CARE TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 79 CANADA POINT OF CARE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 80 CANADA POINT OF CARE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)
FIGURE 81 CANADA POINT OF CARE TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025- 2032)
FIGURE 82 CANADA POINT OF CARE TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 83 U.S. POINT OF CARE TESTING MARKET: COMPANY SHARE 2024 (%)
FIGURE 84 CANADA POINT OF CARE TESTING MARKET: COMPANY SHARE 2024 (%)
